372 related articles for article (PubMed ID: 23263738)
1. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
2. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.
Yang GP; Yuan H; Tang B; Zhang W; Wang LS; Huang ZJ; Ou-Yang DS; Zhang GX; Zhou HH
Acta Pharmacol Sin; 2010 Mar; 31(3):382-6. PubMed ID: 20140004
[TBL] [Abstract][Full Text] [Related]
4. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Gao Y; Zhang LR; Fu Q
Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
[TBL] [Abstract][Full Text] [Related]
7. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
8. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
[TBL] [Abstract][Full Text] [Related]
10. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
Wu X; Gong C; Weinstock J; Cheng J; Hu S; Venners SA; Hsu YH; Wu S; Zha X; Jiang S; Li Y; Pan F; Xu X
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):240S-247S. PubMed ID: 30336686
[TBL] [Abstract][Full Text] [Related]
11. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
[TBL] [Abstract][Full Text] [Related]
12. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH
Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881
[TBL] [Abstract][Full Text] [Related]
13. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.
Hu M; Mak VW; Tomlinson B
Pharmacogenet Genomics; 2012 Nov; 22(11):803-6. PubMed ID: 22668755
[TBL] [Abstract][Full Text] [Related]
14. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
15. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
[TBL] [Abstract][Full Text] [Related]
16. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
17. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
19. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
20. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
